Drug intelligence / Profile preview

DA-007

Development stage: Unknown
Lead developer: Jupiter Wellness
Modality: Small Molecules
Administration: Topical

Overview

DA-007 is a small molecule drug under development for the treatment of chemotherapy-induced alopecia. It is being developed by Applied Biology and is currently in Phase 3 clinical trials. The proposed mechanism of action involves reducing scalp blood perfusion, which may help to decrease hair loss associated with chemotherapy. The precise molecular target and detailed mechanism remain unknown.

Beyond the preview

Go deeper on DA-007.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-007.

Explore the full profile